Sharekhan

#SharekhanFNA #Wipro Q3FY22 results review: Q3 revenue missed estimates, but margin in-line; provided revenue growt… https://t.co/nE4NNaBdL5 #SharekhanFNA #Wipro

#SharekhanFNA #SharekhanResearch retains Buy on #Cadila (PT Rs720) India bizz on a strong footing to stage a double… https://t.co/p7fQwP0Ohw #SharekhanFNA #SharekhanResearch #Cadila

#SharekhanFNA #SharekhanResearch retains Buy on #AbbottIndia (PT Rs22780) Co to sustain double digit growth traject… https://t.co/LVEkhnOInj #SharekhanFNA #SharekhanResearch #AbbottIndia

#SharekhanFNA #SharekhanResearch retains Buy rating on #TorrentPharma (PT Rs3620) Strong growth outlook exists for… https://t.co/oIUsjvIR10 #SharekhanFNA #SharekhanResearch #TorrentPharma

#SharekhanFNA #SharekhanResearch retains Positive view on #CaplinPoint (Upside 30%) Co relatively less impacted by… https://t.co/aajLXTmNIf #SharekhanFNA #SharekhanResearch #CaplinPoint

#SharekhanFNA #SharekhanResearch retains Buy on #GlandPharma (PT Rs 4400) strng gwth in RoW mkts with rev share lik… https://t.co/GDqGHYQGHB #SharekhanFNA #SharekhanResearch #GlandPharma

#SharekhanFNA #SharekhanResearch retains Buy on #IPCALabs (PT Rs 2675) acquisition of stake in #Lykalabs & a Jt mng… https://t.co/WzcJlnN8p0 #SharekhanFNA #SharekhanResearch #IPCALabs #Lykalabs

#SharekhanFNA #SharekhanResearch #Q2FY22 Pharma Review; mixed qtr, results driven by strng gwth in India bizz, US g… https://t.co/0ZNFTKdAGn #SharekhanFNA #SharekhanResearch #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy on #SolaraActivePharma (PT Rs 1615) #Q2FY22 was weak qtr rslts missed… https://t.co/CXVPfcqpSV #SharekhanFNA #SharekhanResearch #SolaraActivePharma #Q2FY22